BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine

Germ-line or somatic inactivation of BRCA1 is a defining feature for a portion of human breast cancers. Here we evaluated the anti-proliferative activity of 198 FDA-approved and experimental drugs against four BRCA1-mutant (HCC1937, MDA-MB-436, SUM1315MO2, and SUM149PT) and four BRCA1-wild-type (MDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yuexi, Helenius, Mikko, Väänänen, Kristiina, Bulanova, Daria, Saarela, Jani, Sokolenko, Anna, Martens, John, Imyanitov, Evgeny, Kuznetsov, Sergey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911578/
https://www.ncbi.nlm.nih.gov/pubmed/27313062
http://dx.doi.org/10.1038/srep28217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911578/
https://www.ncbi.nlm.nih.gov/pubmed/27313062
http://dx.doi.org/10.1038/srep28217

Ejemplares similares